Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 4 1Phase 3 1Phase 1 1

Status

Not yet recruiting 2Unknown 1Terminated 1Recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Colorectal Neoplasms 51Rectal Neoplasms 27Colonic Neoplasms 16Stomach Neoplasms 14Carcinoma, Hepatocellular 14Neoplasm Metastasis 9Adenocarcinoma Of Esophagus 7Esophageal Neoplasms 6Neoplasms 5Cholangiocarcinoma 5Recurrence 3Pancreatic Neoplasms 3Esophageal Squamous Cell Carcinoma 3Digestive System Neoplasms 3Adenocarcinoma 3Ovarian Neoplasms 2Liver Neoplasms 2Intestinal Neoplasms 2Gastrointestinal Neoplasms 2Gastrointestinal Diseases 2Cirrhosis, Familial, with Pulmonary Hypertension 2Biliary Tract Neoplasms 2Peritoneal Neoplasms 1Pancreatic Adenocarcinoma 1Operable T2-3N+M0 Rectal Cancer (Stage III) 1Neurotoxicity Syndromes 1Metastatic Colorectal Adenocarcinoma 1Locally Advanced Pancreatic Carcinoma(LAPC) 1Locally Advanced Colorectal Carcinoma 1Intestinal Diseases 1

Interventions

Gemcitabine 58Cisplatin 32Oxaliplatin 28Fluorouracil 21lenvatinib 19durvalumab 18Capecitabine 17Leucovorin 15pembrolizumab 10tislelizumab 9apatinib 9Floxuridine 8Specimen Handling 7Panitumumab 7Magnetic Resonance Spectroscopy 7Albumin-Bound Paclitaxel 7sintilimab 6pemigatinib 6Radiotherapy 6Irinotecan 6Drug Therapy 6Biopsy 6tremelimumab 5olaparib 5camrelizumab 5Taxes 5S 1 (combination) 5Nivolumab 5Folfox protocol 5Bevacizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Cholangiocarcinoma × Folfox protocol × Clear all
NCT05712356 2026-05-26

BOLSTER

Lisata Therapeutics, Inc.

Phase 2 Terminated
66 enrolled 12 charts
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Disease Progression

NCT06529718 2026-05-19

SEVILLA

UNICANCER

Phase 2 Recruiting
72 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT07353827 2026-01-20

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

Sun Yat-sen University

Phase 2 Not yet recruiting
36 enrolled
Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT06946849 2025-04-27

SED-RO-ICC

Shanghai Zhongshan Hospital

Phase 2 Not yet recruiting
76 enrolled
Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT05535647 2022-09-10

Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
60 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡